Sonus Pharmaceuticals is laying off 16 workers and stopping work on two oncology programs so it can focus its resources on its early-stage drug SN2310 while exploring in-licensing opportunities and strategic transactions. Release
Sonus Pharmaceuticals is laying off 16 workers and stopping work on two oncology programs so it can focus its resources on its early-stage drug SN2310 while exploring in-licensing opportunities and strategic transactions. Release